Embla Medical hfOSSFF 92 ROC (Joel Greenblatt) % is 23.93% as of Mar. 2026, which is 30% below its 10-year median of 34.37. GuruFocus rates OSSFF with a GF Score™ of 92/100 and a GF Value™ of $5.29. The stock has 2 warning signs investors should review. Among 841 Medical Devices & Instruments companies, Embla Medical hf ranks better than 81.93% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Embla Medical hf's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 23.93%.
The historical rank and industry rank for Embla Medical hf's ROC (Joel Greenblatt) % or its related term are showing as below:
OSSFF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 7.49 Med: 34.37 Max: 62.86
Current: 33.52
During the past 13 years, Embla Medical hf's highest ROC (Joel Greenblatt) % was 62.86%. The lowest was 7.49%. And the median was 34.37%.
OSSFF's ROC (Joel Greenblatt) % is ranked better than 81.93% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 3.94
vs OSSFF: 33.52
Embla Medical hf's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 23.80% per year.
Embla Medical hf (OTCPK:OSSFF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Embla Medical hf ROC (Joel Greenblatt) % Related Terms
Embla Medical hf ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Embla Medical hf's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSSFF vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Embla Medical hf's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embla Medical hf ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Embla Medical hf's ROC (Joel Greenblatt) % falls into.
Embla Medical hf ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 23.93% mean?
Embla Medical hf (OSSFF) has a ROC (Joel Greenblatt) % of 23.93% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Embla Medical hf and its competitors. This is 30% below median its historical median of 34.37. Over the past decade, Embla Medical hf's ROC (Joel Greenblatt) % has ranged from 7.49 to 62.86. According to the industry distribution chart, Embla Medical hf ranks #152 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 18.1%.
Is Embla Medical hf's ROC (Joel Greenblatt) % too high?
Embla Medical hf's current ROC (Joel Greenblatt) % of 23.93% is 30% below median its 10-year median of 34.37. Over the past 10 years, this metric has ranged from a low of 7.49 to a high of 62.86. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 3.94. Embla Medical hf's value of 23.93% is 507.4% above this industry median. Based on the distribution chart, Embla Medical hf ranks #152 out of 841 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Embla Medical hf has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Embla Medical hf ranks #152 out of 841 companies for ROC (Joel Greenblatt) %. This places Embla Medical hf in the top 18% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 3.94. Embla Medical hf's value of 23.93% is 507.4% above this benchmark. Historically, Embla Medical hf's own ROC (Joel Greenblatt) % has ranged from 7.49 to 62.86 over the past decade. While the company's 10-year median is 34.37 vs. the industry median of 3.94, Embla Medical hf has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 3.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embla Medical hf's current ROC (Joel Greenblatt) % of 23.93% is 507.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Embla Medical hf and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 3.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embla Medical hf's current ROC (Joel Greenblatt) % is 23.93%, which is 30% below median its own 10-year median of 34.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Embla Medical hf (OSSFF) has a current ROC (Joel Greenblatt) % of 23.93%. The stock's GF Value™ is $5.29, compared to a current price of $4.15 — trading 21.6% below its estimated fair value. The current ROC (Joel Greenblatt) % is 23.93%, which is 30% below median its 10-year median of 34.37 and 507.4% above the Medical Devices & Instruments industry median of 3.94. Embla Medical hf's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Embla Medical hf (OSSFF), the current ROC (Joel Greenblatt) % is 23.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OSSFF) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of $4.15 is trading 21.6% below its estimated GF Value™ of $5.29.
Key valuation signals for OSSFF:
ROC (Joel Greenblatt) %: 23.93% (30% below median its 10-year median of 34.37)
GF Value™: $5.29 vs. price of $4.15 (21.6% below fair value)
Industry Position: 507.4% above the Medical Devices & Instruments median (#152 of 841)
No single metric tells the full story. See the OSSFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score
Get the complete analysis for OSSFF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSSFF has been successfully added to your 
